Immunome, Inc. (NasdaqCM: IMNM)
Health Care · Biotechnology · US
$19.31
-7.61% today · +45.0% 1Y
Immunome, Inc. (NasdaqCM: IMNM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.37B and employs 247 people.
Over the last twelve months the share price has gained 45.0%, trading between 11.55 and 30.06.
Tweenvest scores Immunome, Inc. across four factors: quality 47/100, value 61/100. Its strongest factor is value.
IMNM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.37B
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -2.49
- Dividend yield
- —
- Beta (5Y)
- 2.55
- 52-week high
- $30.06
- 52-week low
- $11.55
- Avg volume (3M)
- —
- Shares outstanding
- 113.58M
- Employees
- 247
- Next earnings
- —
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- ISIN
- US45257U1088
- Founded
- 2006
- Listed since
- Oct 2, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Disc Medicine, Inc.NasdaqGM: IRON | $2.48B | $60.77 | -5.80% |
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.48B | $24.60 | -0.69% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.39B | $29.30 | -3.71% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.39B | $22.21 | -3.39% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.36B | ₩306,000.00 | -5.12% |
| CanSino Biologics Inc.SEHK: 6185 | $2.34B | HK$34.64 | +14.02% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.29B | $3.95 | -7.49% |
| SELLAS Life Sciences Group, Inc.NasdaqCM: SLS | $2.28B | $11.26 | -0.44% |
Figures last refreshed Oct 4, 2026.